Physician profile
Gila Hoffman
NPI 1700316718
$718.92
in general payments reported to CMS, 2019-2025
12 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $162 · 2024: $321 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.24 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.06 | 2023 | |
| Lilly USA, LLC | $94.83 | 2024-2025 | Omvoh |
| Genzyme Corporation | $63.20 | 2024-2025 | |
| Janssen Biotech, INC. | $42.77 | 2025 | Tremfya |
| Ambu INC. | $33.32 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.47 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $23.60 | 2025 | Voquezna |
| Celgene Corporation | $23.07 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $22.33 | 2025 | Entyvio |
| Aimmune Therapeutics, INC. | $21.28 | 2025 | Vowst |
| Janssen Scientific Affairs, LLC | $15.75 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gila Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.